WO2021000950A1 - 外用药组合物及其制备方法 - Google Patents

外用药组合物及其制备方法 Download PDF

Info

Publication number
WO2021000950A1
WO2021000950A1 PCT/CN2020/100217 CN2020100217W WO2021000950A1 WO 2021000950 A1 WO2021000950 A1 WO 2021000950A1 CN 2020100217 W CN2020100217 W CN 2020100217W WO 2021000950 A1 WO2021000950 A1 WO 2021000950A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
preparation
pharmaceutical composition
liver oil
puffer fish
Prior art date
Application number
PCT/CN2020/100217
Other languages
English (en)
French (fr)
Inventor
黄连生
Original Assignee
深圳瑞达生物股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳瑞达生物股份有限公司 filed Critical 深圳瑞达生物股份有限公司
Publication of WO2021000950A1 publication Critical patent/WO2021000950A1/zh

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37Digestive system
    • A61K35/413Gall bladder; Bile
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/60Fish, e.g. seahorses; Fish eggs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/32Burseraceae (Frankincense family)
    • A61K36/324Boswellia, e.g. frankincense
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/32Burseraceae (Frankincense family)
    • A61K36/328Commiphora, e.g. mecca myrrh or balm of Gilead
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484Glycyrrhiza (licorice)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539Scutellaria (skullcap)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718Coptis (goldthread)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/74Rubiaceae (Madder family)
    • A61K36/744Gardenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/756Phellodendron, e.g. corktree
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/889Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders

Definitions

  • the invention relates to the technical field of traditional Chinese medicine formulations, in particular to a pharmaceutical composition for external use and a preparation method thereof.
  • puffer fish liver accounts for as much as one-sixth of the weight of the entire fish, and the liver oil content reaches 60% to 65%. These puffer fish viscera wastes will bring a very sufficient supply of puffer fish liver.
  • the puffer fish liver oil extracted from the puffer fish liver is rich in vitamins and trace elements. Topical application can accelerate the formation of epithelium on the skin defect.
  • the oily substance can form a protective film on the skin surface to prevent bacterial invasion and infection.
  • tetrodotoxin is enriched in puffer fish liver, and it has been proved by a large number of clinical cases that small doses can obtain good analgesic effects.
  • puffer fish cod liver oil has the functions of reducing swelling, detoxification, and dispersing masses and pain.
  • puffer fish liver oil in the prior art has the following problems: Although the application of puffer fish liver oil is occasionally reported, it is usually taken orally or externally to explore its efficacy, and it does not provide one and other combinations. The technical solution used by the distributor is difficult to truly and effectively exert the efficacy and biological activity of puffer fish liver oil, and the comprehensive utilization level is low.
  • the present invention provides a pharmaceutical composition for external use and a preparation method thereof to solve the problems that the existing tetrodotoxin or puffer fish liver oil utilization method is relatively single, cannot fully exert its biological activity, and the comprehensive utilization efficiency is not high.
  • the first aspect of the present invention provides a pharmaceutical composition for external use.
  • the raw material components of the external medicine composition include: puffer fish liver oil, artificial bezoar, scutellaria, coptis, cork, gardenia, dragon's blood, myrrh, frankincense, licorice, borneol and vitamin C.
  • the dosage form of the pharmaceutical composition for external use includes suppositories, ointments, emulsions, pastes, patches and aerosols.
  • the puffer fish liver oil contains 4-12 ppm of tetrodotoxin and its derivatives.
  • the raw material components of the pharmaceutical composition for external use include: 20-60 parts of puffer fish liver oil, 0.15-0.35 parts of artificial bezoar, 3-10 parts of Scutellaria, 3-10 parts of Coptis, 3-10 parts of Phellodendron amurense 10 parts, gardenia 3-10 parts, dragon's blood 1-2 parts, myrrh 3-5 parts, frankincense 3-5 parts, licorice 3-10 parts, borneol 0-0.15 parts, and vitamin C 0-0.2 parts.
  • the raw material components of the external medicine composition include: 54 parts of puffer fish liver oil, 0.15 parts of artificial bezoar, 6 parts of Scutellaria, 6 parts of Coptis, 6 parts of Cork, 6 parts of Gardenia, Dragon's Blood 1.5 parts, 3 parts of myrrh, 3 parts of frankincense, 3 parts of licorice, 0.1 part of borneol, and 0.2 part of vitamin C.
  • the second aspect of the present invention also provides a preparation method of the compound puffer fish liver oil ointment formulation as described above.
  • the preparation method includes the following steps:
  • the solid medicine is crushed to form a medicine powder, and the solid medicine includes artificial bezoar, scutellaria, coptis, cork, gardenia, dragon's blood, myrrh, frankincense and licorice;
  • the steps 1) and 2) have no time limit.
  • the method further comprises: sieving the medicine powder with an aperture of 100 meshes.
  • the preset first temperature is 80 to 90 degrees Celsius; the preset second temperature is 75 to 80 degrees Celsius; and the preset third temperature is 30 to 40 degrees Celsius.
  • the preset stirring time is 4 hours.
  • the raw material components of the compound puffer fish liver oil ointment preparation include: 54 parts of puffer fish liver oil, 0.15 parts of artificial bezoar, 6 parts of Scutellaria, 6 parts of Coptis, 6 parts of Cork, 6 parts of Gardenia, 1.5 parts of Dragon's Blood, 3 parts of Myrrh, 3 parts of Frankincense, 3 parts of Licorice, 0.1 parts of Borneol, 0.2 parts of Vitamin C, 100 parts of Vaseline and 10 parts of Lanolin.
  • the present invention also provides the application of the external pharmaceutical composition of the above-mentioned scheme or the compound puffer fish liver oil ointment preparation prepared by the preparation method in the preparation of a medicine for treating skin diseases, neuralgia sequelae or trauma.
  • the present invention also provides a method for treating neuralgia after herpes zoster, which comprises the following steps: using the external medicine composition of the above scheme or the compound puffer fish liver oil ointment preparation prepared by the preparation method through nerve block combined external application Treatment of neuralgia after herpes zoster.
  • the technical solution provided by the embodiment of the present invention provides a composition of puffer fish liver oil, which uses puffer fish liver oil containing tetrodotoxin as a drug-carrying matrix, and is matched with "prince medicine”, “chen medicine”, “adjuvant medicine” and “make medicine” ”And other compound formulations for external use.
  • the external medicine can achieve better treatment effects for various chronic skin diseases, trauma and trauma infections, and chronic skin diseases that cannot be cured for a long time, and has a good application prospect.
  • Fig. 1 is a schematic diagram of an embodiment of the preparation method of the compound pufferfish cod liver oil ointment preparation provided by the embodiment of the present invention.
  • the present invention provides a pharmaceutical composition for external use, which is compatible with puffer fish liver oil and other traditional Chinese medicine components, has good biological activity, and can be used to treat various chronic skin diseases, traumas, wound infections, and the like.
  • the raw material components of the external medicine composition include: puffer fish liver oil, artificial bezoar, scutellaria, coptis, cork, gardenia, dragon's blood, myrrh, frankincense, licorice, borneol and vitamin C.
  • the selected puffer fish liver oil is rich in tetrodotoxin and its derivatives, and the content is 4-12 ppm.
  • Tetrodotoxin is a strong nerve blocker that specifically blocks Na + channels. When it is located on the outer side of the membrane, it can bind to the sodium ion channel receptor site I to prevent sodium ions from entering the cell, thereby blocking the voltage-dependent sodium channel, affecting the generation and conduction of the cell membrane action potential, and blocking the action potential. To the analgesic effect.
  • artificial bezoar, scutellaria, coptis, cork and gardenia are “prince drugs”. Its main function is to clear away heat and detoxify.
  • Dragon's blood, myrrh, and frankincense are “main medicine”, which mainly play a role in dispelling blood stasis, reducing swelling, and reducing inflammation.
  • the puffer fish liver oil containing tetrodotoxin and its derivatives is an "adjuvant", which can relieve itching, relieve pain and protect against inflammation.
  • "Making medicine” is licorice which plays a reconciling role and borneol which is used as a prescription.
  • the combination of the above formulas can mediate liver qi, reduce swelling and detoxification inside, relieve pain and reduce inflammation outside, promote blood circulation and build muscle, and treat both internally and externally to reduce pain, speed up recovery, and reduce neuralgia sequelae.
  • the external medicine composition obtained through nerve block combined with external application can have a significant effect on patients with post-herpetic neuralgia.
  • it can also produce certain effects on skin diseases such as trauma and trauma infection, chronic skin diseases that cannot be cured for a long time, and various incurable furuncles, pain, gangrene, pus, blisters, sores, scabies, ringworm, inflammation, and itching.
  • the pharmaceutical composition for external use may include the following raw materials in parts by weight: 20-60 parts of puffer fish liver oil, 0.15-0.35 parts of artificial bezoar, 3-10 parts of Scutellariae, 3-10 parts of Coptis Servings, 3 ⁇ 10 parts of Phellodendron chinense, 3 ⁇ 10 parts of Gardenia, 1 ⁇ 2 parts of Dragon's Blood, 3 ⁇ 5 parts of Myrrh, 3 ⁇ 5 parts of Frankincense, 3 ⁇ 10 parts of Licorice, 0 ⁇ 0.15 parts of Borneol, and Vitamin C 0 ⁇ 0.2 copies.
  • the best therapeutic effect can be achieved by using a pharmaceutical composition for external use with such a composition ratio, and can make full use of the nerve-blocking effect of puffer fish liver oil.
  • the pharmaceutical composition for external use can take any suitable dosage form according to actual use needs or market demand, including but not limited to suppositories, ointments, emulsions, pastes, patches, and aerosols.
  • the external medicine composition can be further added with other suitable auxiliary materials to obtain the corresponding dosage form; preferably, when preparing the ointment preparation, petrolatum and lanolin are also added.
  • Fig. 1 is a method flow chart of the preparation method of the compound puffer fish cod liver oil ointment preparation provided by an embodiment of the present invention. As shown in Figure 1, the preparation method includes the following steps:
  • the solid medicine includes artificial bezoar, scutellaria, coptis, cork, gardenia, dragon's blood, myrrh, frankincense and licorice.
  • the present invention after the solid medicine is pulverized, the present invention also includes sieving the pulverized solid medicine to separate the powder with uneven thickness, so as to screen out the medicine powder with uniform particle size; the sieve for screening
  • the pore size is preferably 100 mesh.
  • the oily substances include petrolatum and lanolin.
  • the preparation container can be a medicine preparation container of any suitable volume or material. It can be equipped with heating and stirring devices for performing corresponding functions. Vaseline and lanolin are soft solids before being added, and can be melted by heating to form a viscous paste.
  • the paste is kept agitated so that the drug powder can be sufficiently dispersed in the mixture of petroleum jelly and lanolin.
  • the temperature is lowered to a preset second temperature, and the puffer fish liver oil is added to the preparation container and stirred to melt the puffer fish liver oil.
  • the stirring time is an empirical value, which can be obtained by those skilled in the art according to actual needs or through multiple experiments.
  • the preset stirring time is 4 hours.
  • the first temperature, the second temperature, and the third temperature are also empirical values, which can be adjusted or determined according to actual conditions.
  • the preset first temperature is 80 to 90 degrees Celsius
  • the preset second temperature is 75 to 80 degrees Celsius
  • the preset third temperature is 30 to 40 degrees Celsius.
  • the mixture in the preparation container is filtered while it is hot. Then, it is dispensed into a suitable container and cooled to prepare and obtain the compound pufferfish cod liver oil ointment preparation.
  • the external medicine formula provided by the embodiment of the present invention contains puffer fish liver oil with quantitative tetrodotoxin and fine Chinese medicine powder.
  • the drugs can be absorbed through the skin to clear away heat and detoxify, remove blood stasis and reduce swelling, invigorate blood, build muscle, relieve pain and reduce inflammation, and treat various chronic skin diseases, trauma and trauma infections, and chronic skin diseases that cannot be cured for a long time. A better treatment effect can be achieved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

一种外用药组合物,其原料组分包括:河豚鱼肝油、人工牛黄、黄芩、黄连、黄柏、栀子、血竭、没药、乳香、甘草、冰片以及维生素C。所述外用药对各种慢性皮肤病、外伤及外伤感染、久治不愈的皮肤顽疾、带状疱疹后神经痛都能达到较好的治疗效果。

Description

外用药组合物及其制备方法
本申请要求于2019年07月03日提交中国专利局、申请号为201910592904.0、发明名称为“外用药组合物及其制备方法”的中国专利申请的优先权,其全部内容通过引用结合在本申请中。
技术领域
本发明涉及中药配方的技术领域,尤其涉及一种外用药组合物及其制备方法。
背景技术
随着社会经济生活的不断进步,各类水产或者新的食物品种也开始了快速的发展和进步。在2016年9月5日,农业部办公厅、国家食品药品监督管理总局联合发布了《关于有条件放开养殖红鳍东方鲀和养殖暗纹东方鲀加工经营的通知》。这使得红鳍东方鲀和暗纹东方鲀这些河豚品种可以被端上消费者的餐桌,作为食物被食用。
伴随着河豚市场的开放,人工养殖河豚鱼产业会有快速的发展。这些河豚鱼产业的发展,会极大的增加河豚鱼内脏废弃物。如何有效的利用这些废弃物中的有益成分,实现循环经济和多层次的产业利用是现今非常重要的产业发展目标。例如,河豚鱼肝占整个鱼体重量的六分之一之多,肝油含量达到60%~65%。这些河豚鱼内脏废弃物将会带来非常充足的河豚鱼肝供应。
从河豚鱼肝中提取的河豚鱼肝油中含有丰富的维生素和微量元素,局部应用可加速皮肤缺损部位上皮的形成,油性物质能在皮肤表面形成保护膜防止细菌入侵感染。
而且,河豚鱼肝中富集了河豚毒素,其被大量临床案例证明小剂量使用可以获得良好的镇痛效果。例如,早在古代《中华本草》中就已提及河豚鱼肝油外用涂敷有消肿解毒、散结镇痛的功能。
而且我国最早在八十年代就有河豚鱼油应用于临床治疗骨髓炎、结核性慢性窦道、经久不愈的溃疡创面、灼伤创面的记载,推测其具有抑菌消炎,促进局部血运的作用。
但是,发明人发现现有技术中关于河豚鱼肝油的利用存在如下问题:河豚鱼肝油的应用虽然偶有报道,但是通常都是单独内服或者外用以探究其功效,并未提供一种与其他多种组分配伍使用的技术方案,难以真正有效的发挥河豚鱼肝油的功效和生物活性,综合利用水平较低。
发明内容
针对上述技术问题,本发明提供了一种外用药组合物及其制备方法,以解决现有河豚毒素或者河豚鱼肝油利用方式较为单一,无法充分发挥其生物活性,综合利用效率不高的问题。
本发明的第一方面提供一种外用药组合物。其中,所述外用药组合物的原料组分包括:河豚鱼肝油、人工牛黄、黄苓、黄连、黄柏、栀子、血竭、没药、乳香、甘草、冰片以及维生素C。
优选的,所述外用药组合物的剂型包括栓剂、油膏剂、乳剂、糊剂、贴剂以及气雾剂。
优选的,所述河豚鱼肝油中含有4~12ppm的河豚毒素及其衍生物。
优选的,按重量份计算,所述外用药组合物的原料组分包括:河豚鱼肝油20~60份、人工牛黄0.15~0.35份、黄苓3~10份、黄连3~10份、黄柏3~10份、栀子3~10份、血竭1~2份、没药3~5份、乳香3~5份、甘草3~10份、冰片0~0.15份和维生素C 0~0.2份。
优选的,按重量份计算,所述外用药组合物的原料组分包括:河豚鱼肝油54份、人工牛黄0.15份、黄苓6份、黄连6份、黄柏6份、栀子6份、血竭1.5份、没药3份、乳香3份、甘草3份、冰片0.1份和维生素C 0.2份。
本发明的第二方面还提供了如上所述的一种复方河豚鱼肝油油膏制剂的制备方法。其中,所述制备方法包括如下步骤:
1)粉碎固体药物,形成药物粉末,所述固体药物包括人工牛黄、黄苓、黄连、黄柏、栀子、血竭、没药、乳香以及甘草;
2)在配制容器内加入油性物质并升温到预设的第一温度,以熔化所述油性物质,所述油性物质包括凡士林和羊毛脂;
3)在搅拌条件下,向所述熔化后的油性物质加入所述药物粉末;
4)搅拌至预设的搅拌时间后,降温至预设的第二温度并向所述配制容器加入河豚鱼肝油并搅拌熔化所述河豚鱼肝油;
5)降温至预设的第三温度后,向所述配制容器内加入冰片和维生素C并搅拌均匀;
6)趁热过滤后,冷却所述配制容器内的混合物以制备获得所述复方河豚鱼肝油油膏制剂;
所述步骤1)和步骤2)没有时间顺序的限制。
优选的,在所述粉碎固体药物,形成药物粉末的步骤之后,所述方法还包括:将所述药物粉末过筛,筛网的孔径为100目。
优选的,所述预设的第一温度为80至90摄氏度;所述预设的第二温度为75至80摄氏度;所述预设的第三温度为30至40摄氏度。
优选的,所述预设的搅拌时间为4小时。
优选的,按重量份计算,所述复方河豚鱼肝油油膏制剂的原料组分包括:河豚鱼肝油54份、人工牛黄0.15份、黄苓6份、黄连6份、黄柏6份、栀子6份、血竭1.5份、没药3份、乳香3份、甘草3份、冰片0.1份、维生素C 0.2份、凡士林100份和羊毛脂10份。
本发明还提供了上述方案所述外用药组合物或者所述制备方法制备得到的复方河豚鱼肝油油膏制剂在制备治疗皮肤病、神经痛后遗症或外伤的药物中的应用。
本发明还提供了一种治疗带状疱疹后神经痛的方法,包括以下步骤:采用上述方案所述外用药组合物或者所述制备方法制备得到的复方河豚鱼肝油油膏制剂通过神经阻滞联合外敷治疗带状疱疹后神经痛。
本发明实施例提供的技术方案提供了一种河豚鱼肝油的组合物,将含有河豚毒素的河豚鱼肝油作为载药的基质,搭配“君药”、“臣药”、“佐药”、“使药”等混合制成复合配方的外用药。该外用药对各种慢性皮肤病、外伤及外伤感染、久治不愈的皮肤顽疾都能达到较好的治疗效果,具有良好的应用前景。
附图说明
图1为本发明实施例提供的复方河豚鱼肝油油膏制剂的制备方法的 一个实施例示意图。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
除非另有定义,本说明书所使用的所有的技术和科学术语与属于本发明的技术领域的技术人员通常理解的含义相同。本说明书中在本发明的说明书中所使用的术语只是为了描述具体的实施方式的目的,不是用于限制本发明。本说明书所使用的术语“和/或”包括一个或多个相关的所列项目的任意的和所有的组合。此外,下面所描述的本发明不同实施方式中所涉及的技术特征只要彼此之间未构成冲突就可以相互结合。
本发明实施例中揭露的数值是近似值,而并非确定值。在误差或者实验条件允许的情况下,可以包括在误差范围内的所有值而不限于本发明实施例中公开的具体数值。
本发明实施例中揭露的数值范围用于表示在混合物中组分的相对量以及其他方法实施例中列举的温度或者其他参数的范围。该数值范围内的一个或者多个数值点在适当的条件下取得。
本发明提供了一种外用药组合物,其将河豚鱼肝油与其他的中药成分相互配伍,具有良好的生物活性,可用于治疗各种慢性皮肤病、外伤以及伤口感染等。
该外用药组合物的原料组分包括:河豚鱼肝油、人工牛黄、黄苓、黄连、黄柏、栀子、血竭、没药、乳香、甘草、冰片以及维生素C。
具体的,选用的河豚鱼肝油中富集了河豚毒素及其衍生物,含量为4~12ppm。
河豚毒素是一种强神经阻滞剂,其特异性阻断Na +通道。当其位于膜外侧时,可以与钠离子通道受体部位Ⅰ结合,阻止钠离子进入细胞内,从而阻断电压依赖性钠通道,影响细胞膜动作电位的产生和传导,阻滞动作电位,从而起到镇痛的作用。
在本发明中,人工牛黄、黄芩、黄连、黄柏和栀子为“君药”。其主要起到清热解毒的作用。血竭、没药和乳香为“臣药”,主要起到散瘀消肿、消炎保护的作用。含有河豚毒素及其衍生物的河豚鱼肝油为“佐药”,可以起到止痒止痛,消炎保护的作用。“使药”为起到调和作用的甘草和作为引方的冰片。
上述各配方结合,内里调解肝气、消肿解毒,外里止痛消炎、活血生肌,内外兼治可以达到减少疼痛,加速康复、减少神经痛后遗症等效果。
以带状疱疹治疗为例,传统的西医治疗作用于使用抗病毒和营养神经的药物进行对症治疗。虽然可以在一定程度上减轻病症,但是也存在比较大的副作用,后遗神经痛的发生率较高,存在比较大的局限性。
而采用上述“君臣佐使”相互配伍,制备获得的外用药组合物通过神经阻滞联合外敷治疗可以对带状疱疹后神经痛患者起到显著的疗效。另外,还可以对外伤及外伤感染、久治不愈的皮肤顽疾、难以治愈的各种疔毒、痛、疽、脓、疱、疮、疥、癣、炎、痒等皮肤疾患产生一定的效果。
在较佳实施例中,按重量份计算,所述外用药组合物可以包括如下原料组分:河豚鱼肝油20~60份、人工牛黄0.15~0.35份、黄苓3~10份、黄连3~10份、黄柏3~10份、栀子3~10份、血竭1~2份、没药3~5份、乳香3~5份、甘草3~10份、冰片0~0.15份和维生素C 0~0.2份。
令人惊喜的是,采用这样成分配比的外用药组合物可以取得最佳的治疗效果,能够充分的利用河豚鱼肝油的神经阻滞作用。
在一些实施例中,根据实际的使用需要或者市场需求,该外用药组合物具体可以采用任何合适的剂型,包括但不限于栓剂、油膏剂、乳剂、糊剂、贴剂以及气雾剂等。
具体的,根据所要制备生产的剂型的不同,该外用药组合物还可以进一步的添加有其他合适的辅料以获得相应的剂型;优选的,在制备油膏制剂时,还添加凡士林和羊毛脂。
图1为本发明实施例提供的复方河豚鱼肝油油膏制剂的制备方法的方法流程图。如图1所示,该制备方法包括如下步骤:
110、粉碎固体药物,形成药物粉末。所述固体药物包括人工牛黄、 黄苓、黄连、黄柏、栀子、血竭、没药、乳香以及甘草。
在本发明中,在固体药物粉碎以后,本发明还包括对粉碎后的固体药物过筛,将粗细不均的粉末分离,从而筛选出颗粒大小均一的药物粉末;所述过筛选用的筛网孔径优选为100目。
120、在配制容器内加入油性物质并升温到预设的第一温度,以熔化所述油性物质。所述油性物质包括凡士林和羊毛脂。
所述配制容器具体可以选用任何合适的体积或者材质的药物配制容器。其可以设置有加热和搅拌装置,用于执行相应的功能。凡士林和羊毛脂在加入前为柔软的固体,可以通过升温加热的方式熔化,形成粘稠的膏状物质。
130、在搅拌条件下,向所述熔化后的油性物质加入所述药物粉末。
在药物粉末加入的同时保持对膏状物质的搅拌以使得药物粉末可以充分的被分散到凡士林和羊毛脂的混合物中。
140、搅拌至预设的搅拌时间后,降温至预设的第二温度并向所述配制容器加入河豚鱼肝油并搅拌熔化所述河豚鱼肝油。
该搅拌时间是一个经验性数值,可以由本领域技术人员根据实际情况的需要或者通过多次实验验证获得。在一些实施例中,该预设的搅拌时间为4小时。
150、降温至预设的第三温度后,向所述配制容器内加入冰片和维生素C并搅拌均匀。
相类似的,所述第一温度、第二温度以及第三温度也是经验性数值,可以根据实际情况而调整或者确定。具体的,所述预设的第一温度为80至90摄氏度;所述预设的第二温度为75至80摄氏度;所述预设的第三温度为30至40摄氏度。
160、趁热过滤后,冷却所述配制容器内的混合物以制备获得所述复方河豚鱼肝油油膏制剂。
在冰片溶解完毕以后,趁热过滤所述配制容器内的混合物。然后分装到合适的容器中冷却,从而制备获得所述复方河豚鱼肝油油膏制剂。
基于本发明实施例提供的制备方法和制备系统,提供如下具体实施例 以详细描述该外用药组合物的制备过程。
实施例1:
1)按表1中所示的配方1,称取需要使用的原料。
2)将中药固体药物粉碎。
3)粉碎后得药物粉末在使用前过100目筛。
4)将称量好的凡士林和羊毛脂放入带有加热和搅拌装置的不锈钢配料容器中,加温至80℃直至油性物质完全熔化。
5)在搅拌的情况下,将人工牛黄、黄芩、黄连、黄柏、栀子、血竭、没药、乳香、甘草的药物粉末加入熔化的油性物质中。
6)在药物粉末加入后,保持80℃下,搅拌4小时。
7)降温至75℃后,加入河豚鱼肝油并继续搅拌至溶化。
8)继续降温至30℃后,加入冰片和维生素C,并在此温度下搅拌均匀。
9)待冰片完全溶解后,趁热过滤并冷却至室温得到复方河豚鱼肝油膏。
实施例2:
1)1)按表1中所示的配方2,称取需要使用的原料。
2)将中药固体药物粉碎。
3)粉碎后得药物粉末在使用前过100目筛。
4)将称量好的凡士林和羊毛脂放入带有加热和搅拌装置的不锈钢配料容器中,加温至90℃直至油性物质完全熔化。
5)在搅拌的情况下,将人工牛黄、黄芩、黄连、黄柏、栀子、血竭、没药、乳香、甘草的药物粉末加入熔化的油性物质中。
6)在药物粉末加入后,保持90℃下,搅拌4小时。
7)降温至80℃后,加入河豚鱼肝油并继续搅拌至溶化。
8)继续降温至40℃后,加入冰片和维生素C,并在此温度下搅拌均匀。
9)待冰片完全溶解后,趁热过滤并冷却至室温得到复方河豚鱼肝油。
表1实施例1和实施例2中复方河豚鱼肝油油膏制剂的配方
Figure PCTCN2020100217-appb-000001
Figure PCTCN2020100217-appb-000002
综上所述,本发明实施例提供的外用药配方中含有定量河豚毒素的河豚鱼肝油与中药细粉。制成各种外用剂型以后,可以通过药物透皮吸收,达到清热解毒、散瘀消肿、活血生肌、止痛消炎的作用,对各种慢性皮肤病、外伤及外伤感染、久治不愈的皮肤顽疾都能达到较好的治疗效果。
可以理解的是,对本领域普通技术人员来说,可以根据本发明的技术方案及本发明构思加以等同替换或改变,而所有这些改变或替换都应属于本发明所附的权利要求的保护范围。

Claims (14)

  1. 一种外用药组合物,其特征在于,所述外用药组合物的原料组分包括:河豚鱼肝油、人工牛黄、黄苓、黄连、黄柏、栀子、血竭、没药、乳香、甘草、冰片以及维生素C。
  2. 根据权利要求1所述的外用药组合物,其特征在于,所述外用药组合物的剂型包括栓剂、油膏剂、乳剂、糊剂、贴剂以及气雾剂。
  3. 根据权利要求2所述的外用药组合物,其特征在于,所述油膏剂的辅料为凡士林和羊毛脂。
  4. 根据权利要求1所述的外用药组合物,其特征在于,所述河豚鱼肝油中含有4~12ppm的河豚毒素及其衍生物。
  5. 根据权利要求1所述的外用药组合物,其特征在于,按重量份计算,所述外用药组合物的原料组分包括:
    河豚鱼肝油20~60份、人工牛黄0.15~0.35份、黄苓3~10份、黄连3~10份、黄柏3~10份、栀子3~10份、血竭1~2份、没药3~5份、乳香3~5份、甘草3~10份、冰片0~0.15份和维生素C 0~0.2份。
  6. 根据权利要求3所述的外用药组合物,其特征在于,按重量份计算,所述外用药组合物的原料组分包括:
    河豚鱼肝油54份、人工牛黄0.15份、黄苓6份、黄连6份、黄柏6份、栀子6份、血竭1.5份、没药3份、乳香3份、甘草3份、冰片0.1份、维生素C 0.2份、凡士林100份和羊毛脂10份。
  7. 一种复方河豚鱼肝油油膏制剂的制备方法,其特征在于,包括:
    1)粉碎固体药物,形成药物粉末,所述固体药物包括人工牛黄、黄苓、黄连、黄柏、栀子、血竭、没药、乳香以及甘草;
    2)在配制容器内加入油性物质并升温到预设的第一温度,以熔化所述油性物质,所述油性物质包括凡士林和羊毛脂;
    3)在搅拌条件下,向所述熔化后的油性物质加入所述药物粉末;
    4)搅拌至预设的搅拌时间后,降温至预设的第二温度并向所述配制容器加入河豚鱼肝油并搅拌熔化所述河豚鱼肝油;
    5)降温至预设的第三温度后,向所述配制容器内加入冰片和维生素 C并搅拌均匀;
    6)趁热过滤后,冷却所述配制容器内的混合物以制备获得所述复方河豚鱼肝油油膏制剂。
  8. 根据权利要求6所述的制备方法,其特征在于,在所述粉碎固体药物,形成药物粉末的步骤之后,所述方法还包括:
    将所述药物粉末过筛,筛网的孔径为100目。
  9. 根据权利要求6所述的制备方法,其特征在于,所述预设的第一温度为80至90摄氏度;所述预设的第二温度为75至80摄氏度;所述预设的第三温度为30至40摄氏度。
  10. 根据权利要求6所述的制备方法,其特征在于,所述预设的搅拌时间为4小时。
  11. 根据权利要求7~10任一所述的制备方法,其特征在于,按重量份计算,所述复方河豚鱼肝油油膏制剂外用药组合物的原料组分包括:
    河豚鱼肝油54份、人工牛黄0.15份、黄苓6份、黄连6份、黄柏6份、栀子6份、血竭1.5份、没药3份、乳香3份、甘草3份、冰片0.1份、维生素C 0.2份、凡士林100份和羊毛脂10份。
  12. 根据权利要求7~10任一所述的制备方法,其特征在于,按重量份计算,所述复方河豚鱼肝油油膏制剂外用药组合物的原料组分包括:
    河豚鱼肝油60份、人工牛黄0.25份、黄苓8份、黄连8份、黄柏8份、栀子8份、血竭1.5份、没药4.5份、乳香4.5份、甘草4份、冰片0.12份、维生素C 0.15份、凡士林100份和羊毛脂10份。
  13. 权利要求1~6任意一项所述外用药组合物或者权利要求7~12任意一项所述制备方法制备得到的复方河豚鱼肝油油膏制剂在制备治疗皮肤病、神经痛后遗症或外伤的药物中的应用。
  14. 一种治疗带状疱疹后神经痛的方法,包括以下步骤:采用权利要求1~6任意一项所述外用药组合物或者权利要求7~12任意一项所述制备方法制备得到的复方河豚鱼肝油油膏制剂通过神经阻滞联合外敷治疗带状疱疹后神经痛。
PCT/CN2020/100217 2019-07-03 2020-07-03 外用药组合物及其制备方法 WO2021000950A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910592904.0 2019-07-03
CN201910592904.0A CN110368442A (zh) 2019-07-03 2019-07-03 外用药组合物及其制备方法

Publications (1)

Publication Number Publication Date
WO2021000950A1 true WO2021000950A1 (zh) 2021-01-07

Family

ID=68251706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/100217 WO2021000950A1 (zh) 2019-07-03 2020-07-03 外用药组合物及其制备方法

Country Status (2)

Country Link
CN (1) CN110368442A (zh)
WO (1) WO2021000950A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110368442A (zh) * 2019-07-03 2019-10-25 深圳瑞达生物股份有限公司 外用药组合物及其制备方法
CN110339389A (zh) * 2019-07-08 2019-10-18 生升美高科技(武汉)有限责任公司 一种油性创面敷贴及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101066340A (zh) * 2007-05-16 2007-11-07 苏振芳 复方外用河豚毒素油膏及其制备方法
CN103610920A (zh) * 2013-11-01 2014-03-05 刘斌田 烧烫伤速效喷液及其制备方法
CN107198689A (zh) * 2017-07-11 2017-09-26 东新皓特(北京)生化科技有限公司 用于治疗疼痛病症的河豚毒素药物组合物及外用药
CN110368442A (zh) * 2019-07-03 2019-10-25 深圳瑞达生物股份有限公司 外用药组合物及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102205019B (zh) * 2011-05-16 2013-03-06 郭新潮 烧伤湿润拔毒膏及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101066340A (zh) * 2007-05-16 2007-11-07 苏振芳 复方外用河豚毒素油膏及其制备方法
CN103610920A (zh) * 2013-11-01 2014-03-05 刘斌田 烧烫伤速效喷液及其制备方法
CN107198689A (zh) * 2017-07-11 2017-09-26 东新皓特(北京)生化科技有限公司 用于治疗疼痛病症的河豚毒素药物组合物及外用药
CN110368442A (zh) * 2019-07-03 2019-10-25 深圳瑞达生物股份有限公司 外用药组合物及其制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
XU, HUAI: "Treatment of 113 Cases of Herpes Zoster with Integrated Traditional Chinese and Western Medicine", GUANGMING JOURNAL OF CHINESE MEDICINE, vol. 25, no. 7, 31 July 2010 (2010-07-31), XP055772591 *
YI, QUN: "Treatment of 50 Cases of Herpes Zoster with Modified Picrorhiza Detoxification Casual and Acupuncture", JIANGXI JOURNAL OF TRADITIONAL CHINESE MEDICINE, vol. 39, no. 3, 31 March 2008 (2008-03-31), XP055772592 *
ZHANG, WUBIAO: "Preparation and Clinical Application of Compound Anti-inflammation Analgesics Shengji Ointment", JOURNAL OF PEDIATRIC PHARMACY, vol. 10, no. 5, 31 October 2004 (2004-10-31), pages 55 - 55, XP055772595, DOI: 10.13407/j.cnki.jpp.1672-108x.2004.05.027 *

Also Published As

Publication number Publication date
CN110368442A (zh) 2019-10-25

Similar Documents

Publication Publication Date Title
Chi et al. Chinese herbal medicine for gout: a review of the clinical evidence and pharmacological mechanisms
WO2021000950A1 (zh) 外用药组合物及其制备方法
CN100462092C (zh) 一种外用中药及其制备方法
CN102670939B (zh) 一种治疗家畜疥癣病的复方蜂胶组合物及其制备方法
CN102600305A (zh) 一种治疗猪巴氏杆菌病的复方蜂胶组合物及其制备方法
CN103610977A (zh) 畜禽用高效清瘟败毒药物的制备方法
CN102068653A (zh) 一种治疗肝病的藏药制剂的制备方法
CN101856481A (zh) 一种消肿散结的外用膏剂
CN102716232A (zh) 一种防治鸭病毒性肝炎的中药组合物及其制备方法
CN103055065A (zh) 治疗鱼类肠炎的纯中药组合物及其制备方法
CN102240345A (zh) 一种防治鸡新城疫的中草药复方制剂
CN102327583B (zh) 一种治疗冻疮肿痛未溃的中药
CN102716270A (zh) 一种防治小鹅瘟的中药组合物及其制备方法
CN110882254B (zh) 一种治疗急性胃炎的组合物及其应用
CN109394768B (zh) 一种治疗湿疹的药物及其制备方法
CN1350868A (zh) 一种防治外感风热的药物及其生产方法
CN103417701A (zh) 一种防治对虾烂鳃病的中药超微粉碎散剂及其制备方法
CN103251704A (zh) 痱子粉的配方及其制备方法
CN102973828B (zh) 治疗家禽兔球虫病的复方蜂胶组合物及其制备方法
CN101002821B (zh) 疱疹软膏
CN108553551B (zh) 一种降低ⅱ型糖尿病血糖的姜酮复方微粉制剂及其制备方法
CN1041992C (zh) 抗感灵片制取工艺
CN104940389B (zh) 治疗中华鳖疱疹病的中药制剂及其制备方法
KR20220129202A (ko) 류마티스 질환 치료를 위한 중국 전통 한약조성물
CN111329918A (zh) 一种治疗口腔溃疡的中药组合物及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20834356

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 10.06.2022)

122 Ep: pct application non-entry in european phase

Ref document number: 20834356

Country of ref document: EP

Kind code of ref document: A1